A carregar...
Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
Activating KRAS mutations are present in 25% of human cancer. Although oncogenic Ras was deemed “undruggable” in the past, recent efforts led to the development of pharmacological inhibitors targeting the KRAS(G12C) mutant, which have shown promise in early clinical trials. The development of allele...
Na minha lista:
| Publicado no: | Innovation (Camb) |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7491749/ https://ncbi.nlm.nih.gov/pubmed/32939510 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xinn.2020.100035 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|